FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1737691017> ?p ?o ?g. }

• W1737691017 endingPage "523" @default.
• W1737691017 startingPage "523" @default.
• W1737691017 abstract "Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS® hydromorphone ER) in patients with chronic pain Joris Vandenbossche,1 Ute Richarz,2 Henry M Richards31Clinical Pharmacology, Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium; 2Global Medical Affairs, Janssen-Cilag, Baar, Switzerland; 3Established Products, Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USAObjective: To characterize the steady-state pharmacokinetic profile of hydromorphone extended-release (ER) in patients with chronic pain taking concomitant medications.Methods: This open-label repeat-dose study enrolled 22 patients (mean age, 51.4 years; 81.8% female). All patients were receiving at least one concomitant medication; 86.4% were receiving at least two concomitant medications and 81.8% were receiving at least three. Patients receiving a stable dose of an opioid were converted to hydromorphone ER at a 5:1 ratio (morphine equivalent:hydromorphone). The dose was titrated to adequate analgesia over 3–14 days and stabilized between 8–48 mg. Oral morphine immediate-release was permitted for breakthrough pain. Area under the concentration–time curve from 0–24 hours (AUC0–24), maximum plasma concentration (Cmax), trough plasma concentration (Cmin), average plasma concentration (Cavg), and degree of fluctuation (100 × [(Cmax - Cmin) ÷ Cavg]) were calculated based on data from 14 patients.Results: Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC0–24, 41.1 ng • h/mL; Cmax, 2.6 ng/mL; Cmin, 1.1 ng/mL; Cavg, 1.7 ng/mL; and the degree of fluctuation was 99.6%. The pharmacokinetic profile of hydromorphone ER was linear and consistent with dose proportionality. Mean pain intensity difference scores showed statistically significant improvement from 2–21 hours after dosing. Sixteen (72.7%) patients reported at least one adverse event (AE). The most common were constipation (31.8%), headache (22.7%), and vomiting (13.6%). One patient discontinued treatment due to vomiting. No deaths, serious AEs, or unexpected AEs occurred.Conclusion: These findings replicate and extend the steady-state pharmacokinetic profile of hydromorphone ER, previously characterized in healthy volunteers, to a population of chronic pain patients taking numerous concomitant medications.Keywords: opioid analgesics, steady-state pharmacokinetic profile, pain intensity, concomitant medications" @default.
• W1737691017 created "2016-06-24" @default.
• W1737691017 creator A5021030323 @default.
• W1737691017 creator A5024033448 @default.
• W1737691017 creator A5055736200 @default.
• W1737691017 date "2012-11-01" @default.
• W1737691017 modified "2023-09-26" @default.
• W1737691017 title "Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS® hydromorphone ER) in patients with chronic pain" @default.
• W1737691017 cites W161730860 @default.
• W1737691017 cites W1742696714 @default.
• W1737691017 cites W1788816026 @default.
• W1737691017 cites W1966497215 @default.
• W1737691017 cites W1978635606 @default.
• W1737691017 cites W1978896524 @default.
• W1737691017 cites W1997096794 @default.
• W1737691017 cites W1997699648 @default.
• W1737691017 cites W2001698061 @default.
• W1737691017 cites W2005189485 @default.
• W1737691017 cites W2011223819 @default.
• W1737691017 cites W2018762794 @default.
• W1737691017 cites W2028501562 @default.
• W1737691017 cites W2046967920 @default.
• W1737691017 cites W2059986413 @default.
• W1737691017 cites W2070562467 @default.
• W1737691017 cites W2080902960 @default.
• W1737691017 cites W2086606585 @default.
• W1737691017 cites W2106102418 @default.
• W1737691017 cites W2115984783 @default.
• W1737691017 cites W2131877065 @default.
• W1737691017 cites W2133118804 @default.
• W1737691017 cites W2143221646 @default.
• W1737691017 cites W2164109641 @default.
• W1737691017 cites W2165051741 @default.
• W1737691017 cites W2170465719 @default.
• W1737691017 cites W2280050921 @default.
• W1737691017 doi "https://doi.org/10.2147/jpr.s33807" @default.
• W1737691017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3500920" @default.
• W1737691017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23166450" @default.
• W1737691017 hasPublicationYear "2012" @default.
• W1737691017 type Work @default.
• W1737691017 sameAs 1737691017 @default.
• W1737691017 citedByCount "8" @default.
• W1737691017 countsByYear W17376910172012 @default.
• W1737691017 countsByYear W17376910172013 @default.
• W1737691017 countsByYear W17376910172014 @default.
• W1737691017 countsByYear W17376910172015 @default.
• W1737691017 countsByYear W17376910172016 @default.
• W1737691017 countsByYear W17376910172018 @default.
• W1737691017 countsByYear W17376910172022 @default.
• W1737691017 crossrefType "journal-article" @default.
• W1737691017 hasAuthorship W1737691017A5021030323 @default.
• W1737691017 hasAuthorship W1737691017A5024033448 @default.
• W1737691017 hasAuthorship W1737691017A5055736200 @default.
• W1737691017 hasBestOaLocation W17376910171 @default.
• W1737691017 hasConcept C112705442 @default.
• W1737691017 hasConcept C126322002 @default.
• W1737691017 hasConcept C170493617 @default.
• W1737691017 hasConcept C22979827 @default.
• W1737691017 hasConcept C2777288759 @default.
• W1737691017 hasConcept C2777389121 @default.
• W1737691017 hasConcept C2778335254 @default.
• W1737691017 hasConcept C2779158186 @default.
• W1737691017 hasConcept C2779384505 @default.
• W1737691017 hasConcept C2781063702 @default.
• W1737691017 hasConcept C3019981671 @default.
• W1737691017 hasConcept C42219234 @default.
• W1737691017 hasConcept C71924100 @default.
• W1737691017 hasConcept C76318530 @default.
• W1737691017 hasConcept C98274493 @default.
• W1737691017 hasConceptScore W1737691017C112705442 @default.
• W1737691017 hasConceptScore W1737691017C126322002 @default.
• W1737691017 hasConceptScore W1737691017C170493617 @default.
• W1737691017 hasConceptScore W1737691017C22979827 @default.
• W1737691017 hasConceptScore W1737691017C2777288759 @default.
• W1737691017 hasConceptScore W1737691017C2777389121 @default.
• W1737691017 hasConceptScore W1737691017C2778335254 @default.
• W1737691017 hasConceptScore W1737691017C2779158186 @default.
• W1737691017 hasConceptScore W1737691017C2779384505 @default.
• W1737691017 hasConceptScore W1737691017C2781063702 @default.
• W1737691017 hasConceptScore W1737691017C3019981671 @default.
• W1737691017 hasConceptScore W1737691017C42219234 @default.
• W1737691017 hasConceptScore W1737691017C71924100 @default.
• W1737691017 hasConceptScore W1737691017C76318530 @default.
• W1737691017 hasConceptScore W1737691017C98274493 @default.
• W1737691017 hasLocation W17376910171 @default.
• W1737691017 hasLocation W17376910172 @default.
• W1737691017 hasLocation W17376910173 @default.
• W1737691017 hasLocation W17376910174 @default.
• W1737691017 hasOpenAccess W1737691017 @default.
• W1737691017 hasPrimaryLocation W17376910171 @default.
• W1737691017 hasRelatedWork W1990533335 @default.
• W1737691017 hasRelatedWork W1999842374 @default.
• W1737691017 hasRelatedWork W2004316453 @default.
• W1737691017 hasRelatedWork W2046934157 @default.
• W1737691017 hasRelatedWork W2054172655 @default.
• W1737691017 hasRelatedWork W2080969318 @default.
• W1737691017 hasRelatedWork W2151288869 @default.
• W1737691017 hasRelatedWork W2351154051 @default.

• next